Treatment of Relapsed Adult Acute Lymphoblastic Leukemia with Fludarabine and Cytosine Arabinoside Followed by Granulocyte Colony-Stimulating Factor (FLAG-GCSF)
- 1 January 1997
- journal article
- clinical trial
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 25 (5-6), 579-583
- https://doi.org/10.3109/10428199709039047
Abstract
The aim of the present study was to evaluate the efficacy of the combination of fludarabine 30/mg/m2 + cytarabine 2g/m2 followed by the administration of G-CSF to achieve a complete remission (CR) in patients with relapsed acute lymphoblastic leukemia (ALL). We treated twelve patients in first relapse, overall 10 patients achieved a second CR, one patient showed resistant disease and one patient died during remission induction. The regimen was well tolerated and we observed a short period of neutropenia with a low incidence of myelosuppression-associated problems. Eight patients in second CR received the same chemotherapeutic regimen as consolidation used for the reinduction. In six patients the chemotherapeutic regimen was well tolerated, two patients died, (cerebral hemorrhage in one patient and sepsis in the other). In conclusion the combination of fludarabine, cytarabine and G-CSF has significant antileukemic activity and non hematological toxicities were acceptable. The addition of G-CSF reduced the period of neutropenia obtaining a low incidence of myelosuppression-associated problems.Keywords
This publication has 11 references indexed in Scilit:
- Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemiaCancer, 1993
- Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL)Annals of Hematology, 1993
- Treatment of relapsed or refractory adult acute lymphocytic leukemiaCancer, 1992
- Effect of Granulocyte Colony-Stimulating Factor after Intensive Induction Therapy in Relapsed or Refractory Acute LeukemiaNew England Journal of Medicine, 1990
- Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1990
- Treatment of Relapsed Acute Lymphocytic Leukemia in AdultsHaematology and blood transfusion, 1990
- Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemiaCancer, 1990
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced MyelosuppressionNew England Journal of Medicine, 1988
- Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.Journal of Clinical Oncology, 1986
- Recent Advances in the Biology and Treatment of Acute Lymphoblastic Leukemia in AdultsNew England Journal of Medicine, 1984